HERON THERAPEUTICS, INC. /DE/ — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that HERON THERAPEUTICS, INC. /DE/ filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($17.50M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.38M) | Aug 8, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($2.38M) | Nov 4, 2025 |
| Q1 | 2025 | Mar 31, 2025 | $2.64M | May 6, 2025 |
| Q3 | 2025 | Mar 31, 2025 | $2.64M | Nov 4, 2025 |
| Q2 | 2025 | Mar 31, 2025 | $2.64M | Aug 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($4.85M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($9.24M) | Aug 8, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($9.24M) | Nov 4, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($3.16M) | Aug 8, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($3.16M) | Nov 4, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.16M) | May 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($25.01M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($42.06M) | Aug 6, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($42.06M) | Nov 12, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($32.77M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($32.77M) | May 7, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($32.77M) | Nov 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($41.91M) | Nov 14, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($56.36M) | Nov 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.09M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.64M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2025 | $3.15M | May 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($4.46M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($6.45M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($4.80M) | May 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($24.93M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($42.40M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($33.06M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($41.88M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($49.50M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($62.92M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($51.71M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($60.47M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($52.11M) | May 9, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($58.38M) | Nov 3, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($55.75M) | Aug 9, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($52.73M) | May 10, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($34.85M) | Nov 5, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($51.78M) | Aug 5, 2020 |